Cosmetic Product Safety Reports (CPSRs) play a vital role in the cosmetics industry. CPSRs are mandated by law in numerous countries worldwide, especially in the European Union (EU) and United Kingdom (UK) markets. The reports contain detailed information on ingredients and finished products, ensuring the safety of cosmetic products for consumers.
Brexit has brought about significant changes in the EU and the UK in terms of regulations affiliated with cosmetics, pharmaceuticals, personal care products and medical devices. The UK decided to leave the EU in 2016 and officially left the trading bloc on Jan 31, 2020. Both countries decided to keep a few things unaltered until Dec 31, 2020.
Significant Changes taken place in the Cosmetics Industry in the UK 2021
Some significant changes have taken place in the UK post-Brexit, which are listed below.
The withdrawal of the United Kingdom from the European Union had many concerns. One of them being Regulatory Submissions. To smoothen the submissions process, the EU and the UK have set up a clear set of rules. Many of them are related to the existing and new marketing authorisation applications (MAAs) for CAPs, DCP and MRP, Batch testing, QP Certification, etc. Let us have a look at what Brexit means for the EU and the UK Regulatory Submissions. Here is a clear-cut Brexit impact summary that has recently been published by a consulting firm.
Understanding Post Brexit Scenario for Medical Devices and Appointing a UKRP The Need of An Exclusive Webinar
It is well known that from January 1, 2021, medical devices to be placed on the UK market are obliged to follow a new Regulatory regime. Currently, the UK market is a witness to many Regulatory changes, with the impact of Brexit. The UK’s existing Regulatory Authority, the Medicines and Healthcare Products Regulatory Agency (MHRA), has taken over the European Union (EU) responsibilities, ultimately changing the UK regulations.
On January 31, 2020, the United Kingdom (UK) officially left the European Union (EU) making the Brexit come alive. In the light of Brexit, the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have released certain Regulatory guidelines to ensure both pharmaceutical and medical device manufacturers are ready for the transition period. Here are the industry-wise key insights to be aligned with:
Brexit is just around the corner and the United Kingdom (UK) is all set to leave the European Union (EU). The implementation date of Brexit was yet again postponed to January 31, 2020, after the UK requested more time for preparations. However, if the UK and the EU are able to ratify a withdrawal agreement by the time of Brexit, the UK will have a transition period until December 31, 2020, to set the governance in order.
The impact of Brexit is evident in almost every industry based in the European Union (EU) and the United Kingdom (UK). Pharmaceutical industry too not to be spared. Although the UK is in negotiations with the EU to streamline the transitions, the European Medicines Agency (EMA) has requested the pharmaceutical marketing authorization holders (MAHs) to stay prepared in advance to ensure continued supply of medicines.
The impact of Brexit has been a major topic for debates amongst the industry experts for the past two years. It has left companies on both the sides, the United Kingdom (UK) and Europe, hanging on a loose thread. As the date of Brexit is drawing closer, industries are aggressively looking for contingency plans for sustaining their business, if the UK leaves with a ‘no-deal’. Coming to the scenario of Life Sciences regulations, if the UK leaves the European Union (EU) with a no-deal, the former will no longer be a member of the EU medicines and medical device Regulatory networks.
With each year, Life Sciences industry is transforming in unpredictable ways, of course it is to better the end-user’s safety. The industry is progressing with technological advancements and the health authorities are equally striving to upgrade the existing Regulatory frameworks to align with market requirements. The Agencies are considering the industry point of view, too, to simplify the regulations. We have seen many such regulations in 2018. But what’s there in 2019?